Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 myocardial protection solution in pediatric cyanotic congenital heart disease surgery
ChiCTR2500102959Phase 4Not yet recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of coenzyme q10 in Cyanotic heart disease (CCHD) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Left ventricular ejection fraction. Planned start May 2025; status: not yet recruiting.
02
Drugs
coenzyme q10
03
Conditions
Cyanotic heart disease (CCHD)
Beyond the preview
Go deeper on ChiCTR2500102959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102959.